Clinical Trial Update: Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B [Phase 3]

View source ↗

Summary

Phase 3 study evaluating safety, immunogenicity and reactogenicity of an adjuvanted recombinant Hepatitis B vaccine with a new formulation alongside Engerix-B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Engerix-B (hepatitis B vaccine)
• Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) (Hepatitis B vaccine, recombinant)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B | Phase 3 | Status: COMPLETED